48001-001: Results for Malaria Elimination and Control of Communicable Disease Threats in Asia and the Pacific | Asian Development Bank

Regional: Results for Malaria Elimination and Control of Communicable Disease Threats in Asia and the Pacific

Sovereign (Public) Project | 48001-001 Status: Active

The TA will assist AP countries to decrease communicable diseases in Asia and the Pacific and to build capacity to work together across borders to strengthen prevention and response to communicable diseases. Given the initial focus on malaria, the GMS countries currently at risk of spread of AR malaria, as well as the other AP countries with endemic malaria transmission, will be prioritized under the RETA. The TA will be coordinated with RETA 8485: Strengthening Regional Response to Malaria and Other Communicable Diseases.

Project Details

Project Officer
Roth, Susann SDSC Request for information
Country
  • Regional
Modality
  • Technical Assistance
Sector
  • Health
 
Project Name Results for Malaria Elimination and Control of Communicable Disease Threats in Asia and the Pacific
Project Number 48001-001
Country Regional
Project Status Active
Project Type / Modality of Assistance Technical Assistance
Source of Funding / Amount
TA 8763-REG: Results for Malaria Elimination and Control of Communicable Disease Threats in Asia and the Pacific (RECAP)
Regional Malaria and Other Communicable Disease Threats Trust Fund under the Health Financing Partnership Facility US$ 12.00 million
Strategic Agendas Environmentally sustainable growth
Inclusive economic growth
Regional integration
Drivers of Change Governance and capacity development
Knowledge solutions
Partnerships
Private sector development
Sector / Subsector

Health - Disease control of communicable disease

Gender Equity and Mainstreaming No gender elements
Description

The TA will assist AP countries to decrease communicable diseases in Asia and the Pacific and to build capacity to work together across borders to strengthen prevention and response to communicable diseases. Given the initial focus on malaria, the GMS countries currently at risk of spread of AR malaria, as well as the other AP countries with endemic malaria transmission, will be prioritized under the RETA. The TA will be coordinated with RETA 8485: Strengthening Regional Response to Malaria and Other Communicable Diseases.

A regional approach is justified by the following: (i) countries or entire regions often face common challenges or limitations that either require cooperation to resolve them or they can more efficiently be addressed through pooling resources and sharing knowledge; (ii) all countries face certain limitations in containing the spread of infections within and from outside their borders, limiting their ability to control communicable diseases; (iii) programs to prevent malaria, tuberculosis, HIV/AIDS and other infectious diseases are regional public goods (RPGs) in the sense that there are shared benefits (good spillovers) and shared costs (bad spillovers); (iv) artemisinin efficacy represents a _commons_, e.g., a shared good that requires the cooperation of all to contain the development of drug resistance; (v) regional cooperation provides economies of scale and greater leverage; and (vi) regional cooperation is instrumental in transferring technology and knowledge.

Project Rationale and Linkage to Country/Regional Strategy

Increased regional and economic integration is a key driver of drug-resistant malaria. In this region, most malaria occurs in or near forested areas, which are largely along the borders between countries. Transport corridors and trade networks are developing fast, bringing new populations into and through these areas and potentially into contact with resistant parasites. Migrant and mobile workers, often with little immunity to malaria and inadequate access to health services, are most affected.

Due to the promise of malaria elimination, and also due to the threat of drug-resistance, malaria has gained the attention of regional leaders. At the 8th East Asian Summit (EAS) held last 10 October 2013 in Bandar Seri Begawan, Brunei Darussalam, heads of states present reiterated their commitment to a declaration made at the 7th EAS on regional responses to malaria control, addressing resistance to antimalarial medicines, and welcomed the establishment of the Asian Pacific Leaders Malaria Alliance (APLMA), naming the ADB as the secretariat. This unprecedented level of political support suggests that the time is right for a regional push to address this disease and to use common ground with other communicable diseases to strengthen regional collaboration on public health issues. Regional leadership needs to be used and actively supported to enable it to have the greatest possible impact. This includes strengthening the work on communicable diseases and public goods in health of ASEAN and other regional bodies.

A broad coalition of countries, donors, private sector and civil society organizations are engaged in malaria control as well as specific action to contain resistant parasites in the GMS. The World Health Organization (WHO) has drawn up a global strategy for tackling resistance. Countries have their own malaria plans in line with this, and with WHO's most recent framework for action, the 2013 Emergency Response to Artemisinin Resistance (ERAR), WHO is setting up a technical hub in Phnom Penh to support GMS countries in these efforts. Given the importance of the issue, several development partners are supporting work on drug resistance, each broadly helping to meet different needs, including US President's Malaria Initiative, supporting work on reducing counterfeit drugs, surveillance for drug resistant strains of malaria, and border area program; the Bill and Melinda Gates Foundation (BMGF), which finances operations research and new surveillance techniques for identifying drug resistant cases and areas; the Australian government which supports regional WHO offices to expand malaria activities, as well as the UK Department for International Development (DFID) which finances access to quality malaria commodities activities in Myanmar and Cambodia. In addition, a 3-year $100M (2014 2016) grant from the Global Fund for AIDS, Tuberculosis and Malaria (GFATM) is addressing the action gap on drug-resistance across GMS.

However, this support is mostly at the country level and does not sufficiently meet the need to act regionally. Large funding gaps exist and are estimated at more than $200M in the GMS countries to contain drug resistant malaria alone, not including additional funding needed to reach malaria elimination goals or other communicable diseases control (CDC) efforts. These estimates also do not include the funding needed for regional actions, such as strengthened cross-border information sharing, better availability of quality drugs, strengthening the capacity of regulatory agencies, elimination of artemisinin monotherapy in the informal private sector and the need to address market failures where governments and private companies do not have the incentives nor capacity to provide quality health services. In addition, regional action brings greater economies of scale and coordination. Comprehensive consultations with DMCs, development partners, NGOs, centers of excellence and research institutes have found that focused regional initiatives are needed to strengthen malaria and CDC in Asia and the Pacific. These areas of work will be covered in the proposed TA through activities that:

-strengthen political leadership and sustain regional financing for malaria and other communicable diseases;

-improve affordability, availability and use of quality medicine and technologies for malaria and other communicable diseases;

-improve application of ICT and innovative technology for evidence-based programs, including better surveillance of hard to reach populations and health systems efficiencies; and

-increase collaboration with private sector and civil society on mitigating negative health impacts from large infrastructure development.

The TA aims to address the above key issues and will be implemented in close coordination with existing activities of other development partners, ADB's support for the APLMA, other activities under the ADB's Regional Malaria and Other Communicable Disease Threats Trust Fund (RMTF) under the Health Financing Partnership Facility, and the work of other ADB departments. The TA will ensure that duplication of efforts is minimized and that all activities are complementary, well-coordinated and strengthen ongoing malaria and other communicable diseases programs. The TA builds on ADB's comparative strengths in (i) facilitating regional cooperation and integration; (ii) mobilizing financing; (iii) engaging in policy dialogue with Ministries of Finance to increase and sustain their own public expenditure; and (iv) engaging the private sector which will be critical in the areas of improving malaria information and availability of drugs and commodities. These strengths have been evidenced in ADB's effective and efficient response to CD threats in Asia and the Pacific, including response to HIV and AIDS and to avian influenza and SARS, and ADB's leadership role on the executive committee of the Regional Steering Committee for the GFATM $100 million GMS grant.

Impact Improved health status of the population in Asia and the Pacific (A).
Project Outcome
Description of Outcome Reduced risk to the AP region and globally from drug resistant malaria and other CD threats
Progress Toward Outcome The outcome is reduced risk to the Asia and Pacific region and globally from drug-resistant malaria and other communicable disease threats. RECAP aims to deliver four outputs.
Implementation Progress
Description of Project Outputs

Strengthened regional leadership and financing for malaria and CD threats

Increased availability, and use of quality assured commodities appropriate to internationally agreed guidelines for malaria and other CD threats

Increased availability and use of quality information, tools and technologies on malaria and other CD threats

Improved capacity to detect and respond to drug-resistant malaria and other CD threats

Communicable diseases addressed in large commercial and infrastructure projects

Status of Implementation Progress (Outputs, Activities, and Issues) 1 - Ensuring quality data for the APLMA Leader's Dashboard. Development of malaria elimination business cases, transmission models and program efficiencies tools finalized in collaboration with UCSF, MORU and APLMA. 2 - Regulatory system profiling tool developed and applied in GMS countries. Capacity development is ongoing. Collaboration with WHO and USP on SSFFC reporting is ongoing. 3. Capacity development and ICT solutions are applied in Viet Nam, Cambodia, Lao PDR and Myanmar. Aim is to achieve convergence of standards and interoperability of vertical diseases information systems.Solutions include geo-enabling the health information system, development of Open HIE architecture, and health IT governance frameworks, assessment of unique health identification. Collaborations with AeHIN and WHO are ongoing. 4. Health Impact Assessment capacity development, policy dialogue and demonstration projects are ongoing in GMS countries.
Geographical Location Regional
Summary of Environmental and Social Aspects
Environmental Aspects
Involuntary Resettlement
Indigenous Peoples
Stakeholder Communication, Participation, and Consultation
During Project Design Regional leaders have committed to tackling malaria eliniation, as evidenced in the outcome statement of the 8th East Asian Summit in October 2013, and welcomed the establishment of the Asia Pacific Leaders Malaria Alliance (APLMA) with ADB as the secretariat. This level of political support suggests the time is right for a regional push to address this disease and to use common ground with other communicable diseases to strengthen regional collaboration on public health issues. On this note, the TA will be implemented in close coordination with other development partners, following the direction of the regional leaders' commitment.
During Project Implementation A major change in scope in the regional capacity development technical assistance (TA) for Results for Malaria Elimination and Control of Communicable Disease Threats in Asia and the Pacific (RECAP) was approved on 2 October 2015. The major changes are (i) reduction in the TA amount from $18 million to $12 million; (ii) scaling down and adjusting of the TA's scope by partial cancellation of some activities and consulting services under outputs 2, 3, and 4; and (iii) reallocation of TA proceeds as best suited fo DMCs. These changes were done in consultation will all key stakeholders and in consideration of DMCs and project beneficiaries. The Regional Malaria and other Communicable Diseases Threats Trust Fund (RMTF) financing partners (governments of Australia, Canada, and the United Kingdom through DFID) were also consulted as programming was done based on the donors' financial commitments documented in the partnership MOU. Detailed RMTF annual reports, which include details of the activities of this TA are available upon request.
Responsible ADB Officer Roth, Susann
Responsible ADB Department SDSC
Responsible ADB Division SDSC-HEA
Executing Agencies
Asian Development Bank
6 ADB Avenue,
Mandaluyong City 1550, Philippines
Timetable
Concept Clearance 04 Aug 2014
Fact Finding 02 Jun 2014 to 19 Jun 2014
MRM -
Approval 20 Nov 2014
Last Review Mission -
Last PDS Update 28 Jul 2017

TA 8763-REG

Milestones
Approval Signing Date Effectivity Date Closing
Original Revised Actual
20 Nov 2014 - 20 Nov 2014 31 Dec 2017 30 Jun 2018 -
Financing Plan/TA Utilization Cumulative Disbursements
ADB Cofinancing Counterpart Total Date Amount
Gov Beneficiaries Project Sponsor Others
0.00 12,000,000.00 0.00 0.00 0.00 0.00 12,000,000.00 20 Nov 2014 6,497,604.53

Project Data Sheets (PDS) contain summary information on the project or program. Because the PDS is a work in progress, some information may not be included in its initial version but will be added as it becomes available. Information about proposed projects is tentative and indicative.

The Public Communications Policy (PCP) recognizes that transparency and accountability are essential to development effectiveness. It establishes the disclosure requirements for documents and information ADB produces or requires to be produced.

The Accountability Mechanism provides a forum where people adversely affected by ADB-assisted projects can voice and seek solutions to their problems and report alleged noncompliance of ADB's operational policies and procedures.

In preparing any country program or strategy, financing any project, or by making any designation of, or reference to, a particular territory or geographic area in this document, the Asian Development Bank does not intend to make any judgments as to the legal or other status of any territory or area.

Safeguard Documents See also: Safeguards

Safeguard documents provided at the time of project/facility approval may also be found in the list of linked documents provided with the Report and Recommendation of the President.

None currently available.

Evaluation Documents See also: Independent Evaluation

None currently available.

Related Publications


The Public Communications Policy (PCP) establishes the disclosure requirements for documents and information ADB produces or requires to be produced in its operations to facilitate stakeholder participation in ADB's decision-making. For more information, refer to the Safeguard Policy Statement, Operations Manual F1, and Operations Manual L3.

Requests for information may also be directed to the InfoUnit.

Tenders

Tender Title Type Status Posting Date Deadline
HIA Expert (Research and Development) Individual - Consulting Closed 28 Jun 2017 07 Jul 2017
HIA coordinator (Cambodia) Individual - Consulting Closed 26 Jul 2017 06 Aug 2017
Health Impact Assessment Expert (Partnership and Advocacy) Individual - Consulting Closed 27 Jul 2017 02 Aug 2017
Results for Malaria Elimination and Control of Communicable Disease Threats in Asia and the Pacific Individual - Consulting Closed 03 Aug 2017 09 Aug 2017
Public Health Administrative and Research Assistant Individual - Consulting Active 08 Sep 2017 14 Sep 2017

Contracts Awarded

Contract Title Approval Number Contract Date Contractor Contractor Address Executing Agency Contract Description Total Contract Amount (US$) Contract Amount Financed by ADB (US$)
Capacity Development Technical Assistance 8763 05 Oct 2015 Duke-NUS Graduate Medical School Singapore (Singapore) Centre of Regulatory Excellence, Level 5 8, College Road, 169857 Singapore Asian Development Bank 2060000
Capacity Development Technical Assistance 8763 18 Jul 2016 University of Oxford (United Kingdom) University Offices, Wellington Square Oxford OX12JD United Kingdom Asian Development Bank 618546